HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Chan, D. W. Articles by Sokoll, L. J. Search for Related Content PubMed PubMed Citation Articles by Chan, D. W. Articles by Sokoll, L. J. Related Collections Proteomics and Protein Markers

WHO First International Standards for Prostate-specific Antigen: The Beginning of the End for Assay Discrepancies?

The Johns Hopkins Medical Institutions, Baltimore, MD 21287
^a Address correspondence to this author at: Division of Clinical Chemistry, Department of Pathology, The Johns Hopkins Medical Institutions, 600 N. Wolfe St., Meyer B-121, Baltimore, MD 21287. Fax 410-955-0767; e-mail dchan@jhmi.edu.

Despite the success of prostate-specific antigen (PSA) as a tumor marker for the early detection and monitoring of disease in prostate cancer, both clinical and analytical limitations of PSA remain (1). Since the introduction of assays for total PSA in the mid-1980s, assay results have been found to differ among manufacturers (2)(3). Much has been learned in the last two decades about the biology of PSA and the molecular forms of PSA present in serum. Differences among assays still persist, however, even among assays from the same manufacturer that have the same antibodies but different assay formats. With the availability of the First International Standards from WHO, is this the beginning of the end for assay discrepancies?

The lack of standardization of PSA was recognized early on as contributing to disparities among assays. Similar to some other tumor markers, a lack of defined antigens, differences in calibrator composition and specific molecular forms, and differences in calibrator assignments as well as the lack of a reference method are some of the issues hampering assay standardization. The lack of standardization of PSA prompted several organizations as well as individual researchers to convene meetings and conferences to address the issue.

The Second Stanford Conference on International Standardization of Prostate-specific Antigen (4) was held in 1994. At this conference, the use of a standard, prepared at Stanford by Tom Stamey, consisting of 90% purified PSA-₁-antichymotrypsin (ACT) and 10% free PSA (90:10) on a molar basis was proposed with the rationale that these . . . [Full Text of this Article]

Acknowledgments

References

The following articles in journals at HighWire Press have cited this article:

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				D. Ulmert, A. M. Serio, M. F. O'Brien, C. Becker, J. A. Eastham, P. T. Scardino, T. Bjork, G. Berglund, A. J. Vickers, and H. Lilja Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population J. Clin. Oncol., February 20, 2008; 26(6): 835 - 841. [Abstract] [Full Text] [PDF]

				S. A.R. Kort, F. Martens, H. Vanpoucke, H. L. van Duijnhoven, and M. A. Blankenstein Comparison of 6 Automated Assays for Total and Free Prostate-Specific Antigen with Special Reference to Their Reactivity toward the WHO 96/670 Reference Preparation Clin. Chem., August 1, 2006; 52(8): 1568 - 1574. [Abstract] [Full Text] [PDF]

				C. Stephan, M. Klaas, C. Muller, D. Schnorr, S. A. Loening, and K. Jung Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update Clin. Chem., January 1, 2006; 52(1): 59 - 64. [Abstract] [Full Text] [PDF]

				A. Semjonow, F. Oberpenning, C. Weining, M. Schon, B. Brandt, G. De Angelis, A. Heinecke, M. Hamm, P. Stieber, L. Hertle, et al. Do Modifications of Nonequimolar Assays for Total Prostate-specific Antigen Improve Detection of Prostate Cancer? Clin. Chem., August 1, 2001; 47(8): 1472 - 1475. [Full Text] [PDF]